Tartu University Hospital, Children's Clinic
Welcome,         Profile    Billing    Logout  
 17 Trials 
33 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Smith, Cameron R
NCT03632044: Evaluation of Trigeminal Nerve Blockade

Enrolling by invitation
4
40
US
Ropivacaine, Naropin, Sham Comparator, Control
University of Florida
Mouth Abnormalities, Cleft Palate, Birth Defect
10/25
10/25
DIAGNODE-3, NCT05018585 / 2021-002731-32: A Phase III Study to Investigate If the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed with Type 1 Diabetes

Recruiting
3
330
Europe, US, RoW
Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Diamyd, Colecalciferol 2000 IU, Divisun 2000 IU, Placebo
Diamyd Medical AB
Type 1 Diabetes Mellitus
12/27
12/27
RESCUE, NCT05307328 / 2021-006184-19: SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

Active, not recruiting
2
26
Europe, US
SPI-62, Placebo
Sparrow Pharmaceuticals, Sparrow Pharmaceuticals, Inc.
Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, Cortisol Excess, Cortisol; Hypersecretion, Cortisol Overproduction, Ectopic ACTH Secretion
12/24
12/25
ACSPIRE, NCT05436639 / 2022-000748-32: SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

Active, not recruiting
2
30
Europe, US
SPI-62 dose
Sparrow Pharmaceuticals, Sparrow Pharmaceuticals, Inc.
Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome, ACTH-Independent Adrenal Cushing Syndrome, Somatic
12/24
12/25
FESS, NCT03970655: Functional Endoscopic Sinus Surgery Study

Recruiting
1/2
80
US
Bupivacaine or Ropivacaine with epinephrine plus dexamethasone - Group 1, Bupivacaine or Ropivacaine with epinephrine plus dexamethasone - Group 2
University of Florida
Chronic Rhinosinusitis (Diagnosis)
12/25
12/26
REVITA-T2Di, NCT04419779: Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

Recruiting
N/A
320
Europe, US
Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham)
Fractyl Health Inc.
Type 2 Diabetes
06/25
01/26
NCT03310528: Gastric Ultrasound for Estimation of the Aspiration Risk Study

Recruiting
N/A
200
US
Interview questionnaire, Gastric ultrasound exam
University of Florida
Respiratory Aspiration of Gastric Contents
07/25
07/26
LINC6, NCT05382156: Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome

Active, not recruiting
N/A
206
Europe, US
Osilodrostat, Isturisa
RECORDATI GROUP
Endogenous Cushing's Syndrome
06/27
08/27
Kipnes, Mark
MKC-TI-193, NCT05904743: INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes

Completed
4
141
US
Afrezza, Technosphere Insulin, insulin degludec, Rapid-acting Insulin Analog, any FDA approved Rapid-acting Insulin Analog, Basal Insulin, any FDA approved Basal Insulin
Mannkind Corporation, Jaeb Center for Health Research
Diabetes Mellitus, Type 1
03/24
06/24
INHALE-1, NCT04974528: Afrezza® Study in Pediatrics

Active, not recruiting
3
319
US
Afrezza, Technosphere Insulin, Rapid-acting Insulin Analog, insulin aspart, insulin lispro, insulin glulisine, Novolog®, Fiasp®, Humalog®, Admelog®, Apidra®, Basal Insulin, insulin glargine, insulin degludec, insulin detemir, Lantus®, Abasaglar®, Basaglar®, Semglee®, Toujeo®, Tresiba®, Levemir®
Mannkind Corporation, Jaeb Center for Health Research
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
10/24
05/25
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

Active, not recruiting
3
1500
Europe, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Type 2 Diabetes
08/25
08/25
DIAGNODE-3, NCT05018585 / 2021-002731-32: A Phase III Study to Investigate If the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed with Type 1 Diabetes

Recruiting
3
330
Europe, US, RoW
Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Diamyd, Colecalciferol 2000 IU, Divisun 2000 IU, Placebo
Diamyd Medical AB
Type 1 Diabetes Mellitus
12/27
12/27
LEGEND, NCT05232071: Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

Completed
2
42
Europe, US
IVA337, Lanifibranor, Placebo, Empagliflozin, Jardiance
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
03/24
06/24
ZONE, NCT05762107: A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes

Recruiting
2
186
Canada, US
Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg
Zucara Therapeutics Inc.
Type 1 Diabetes Mellitus with Hypoglycemia
06/25
07/25
NCT04720170: Exploratory Study of the Efficacy of Standard of Care Revascularization of the Lower Extremity

Not yet recruiting
N/A
30
US
Revascularization
Diabetes and Glandular Disease Clinic, Modern Vascular, LLC
Diabetic Peripheral Neuropathy
07/21
09/21
NCT05403502: Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 Diabetes

Completed
N/A
183
US
t:slim X2 insulin pump with Control-IQ technology 1.5
Tandem Diabetes Care, Inc., Eli Lilly and Company, Jaeb Center for Health Research
Type 1 Diabetes
08/23
08/23
SECURE-T2D, NCT05815342: OP5-005 Using Omnipod 5 in Adults With Type 2

Completed
N/A
343
US
Omnipod 5 Automated Glucose Control System
Insulet Corporation, Jaeb Center for Health Research
Type2 Diabetes
03/24
03/24
NCT05325294: Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev®

Completed
N/A
244
US
MiniMed 780G System
Medtronic Diabetes, Eli Lilly and Company
Type 1 Diabetes
01/24
01/24
NCT02748018: Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home

Active, not recruiting
N/A
280
Europe, Canada, US, RoW
670G and 770G Insulin Pump, Subject's Current Diabetes Therapy
Medtronic Diabetes
Type 1 Diabetes
03/25
06/25
NCT05224258: Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp®

Completed
N/A
240
Canada, US, RoW
MiniMed 780G System
Medtronic Diabetes
Type 1 Diabetes
06/24
06/24
NCT06719531: SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients with Type 1 and Type 2 Diabetes

Not yet recruiting
N/A
1500
US
Continuous Glucose Monitoring
Medtronic Diabetes
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
12/25
12/25
Metsvaht, Tuuli
TREOCAPA, NCT04459117 / 2019-004297-26: Prophylactic Treatment of the Ductus Arteriosus in Preterm Infants by Acetaminophen

Active, not recruiting
2/3
824
Europe
Acetaminophen, NACL 0.9%
Institut National de la Santé Et de la Recherche Médicale, France, UPCET, PARTNERS for International clinical Research, European Fundation for the Care of the Newborn Infants, Connect for Children
Patency of the Ductus Arteriosus, Acetaminophen, Extreme Prematurity
07/24
07/24
NCT03648437 / 2018-000565-36: Paracetamol And Ibuprofen/Indomethacin in Closing Patent Ductus Arteriosus

Terminated
1
22
Europe
Paracetamol 10Mg/mL, Paracetamol Fresenius Kabi 10mg/mL infusion solution, 0.45% Sodium Chloride, NATRIUMKLORID BRAUN 4,5 mg/mL infusion solution, Ibuprofen, Pedea 5mg/mL injection solution, Indomethacin, Liometacen 50mg/2mL injection
University of Oulu, Helsinki University Central Hospital, Turku University Hospital, Tampere University Hospital
Patent Ductus Arteriosus
10/24
10/24
Bettin, Daniela
DIAGNODE-3, NCT05018585 / 2021-002731-32: A Phase III Study to Investigate If the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed with Type 1 Diabetes

Recruiting
3
330
Europe, US, RoW
Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Diamyd, Colecalciferol 2000 IU, Divisun 2000 IU, Placebo
Diamyd Medical AB
Type 1 Diabetes Mellitus
12/27
12/27
SCOUT-II, NCT03225612: Safety and Performance of the Trialign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)

Recruiting
N/A
60
Europe
Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)
Mitralign, Inc., Genae, Regulatory and Clinical Research Institute Inc, CardioVascular Research Foundation, Korea
Chronic Symptomatic Functional Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Heart Valve Disease
06/18
11/22
NCT02880631: BAROSTIM THERAPY™ In Resistant Hypertension

Recruiting
N/A
500
Europe
BAROSTIM NEO™ System
CVRx, Inc.
Hypertension
07/24
07/24
Gallagher, Mary
INHALE-1, NCT04974528: Afrezza® Study in Pediatrics

Active, not recruiting
3
319
US
Afrezza, Technosphere Insulin, Rapid-acting Insulin Analog, insulin aspart, insulin lispro, insulin glulisine, Novolog®, Fiasp®, Humalog®, Admelog®, Apidra®, Basal Insulin, insulin glargine, insulin degludec, insulin detemir, Lantus®, Abasaglar®, Basaglar®, Semglee®, Toujeo®, Tresiba®, Levemir®
Mannkind Corporation, Jaeb Center for Health Research
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
10/24
05/25
DIAGNODE-3, NCT05018585 / 2021-002731-32: A Phase III Study to Investigate If the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed with Type 1 Diabetes

Recruiting
3
330
Europe, US, RoW
Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Diamyd, Colecalciferol 2000 IU, Divisun 2000 IU, Placebo
Diamyd Medical AB
Type 1 Diabetes Mellitus
12/27
12/27
NCT06362265: A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus

Recruiting
1
22
US
LY3209590
Eli Lilly and Company
Type 2 Diabetes Mellitus
11/26
11/26
NCT03653013: Neuropsychological Consultation as Part of Pediatric Diabetes Care: Does it Improve Glycemic Control and Family Functioning?

Completed
N/A
50
US
Usual standard of care, Control Group, Neuropsychological Consultation
NYU Langone Health
Diabetes, Glycinemia
08/22
08/23
Puchalska, Marta
DIAGNODE-3, NCT05018585 / 2021-002731-32: A Phase III Study to Investigate If the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed with Type 1 Diabetes

Recruiting
3
330
Europe, US, RoW
Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Diamyd, Colecalciferol 2000 IU, Divisun 2000 IU, Placebo
Diamyd Medical AB
Type 1 Diabetes Mellitus
12/27
12/27
Pickett, Kathi
DIAGNODE-3, NCT05018585 / 2021-002731-32: A Phase III Study to Investigate If the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed with Type 1 Diabetes

Recruiting
3
330
Europe, US, RoW
Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Diamyd, Colecalciferol 2000 IU, Divisun 2000 IU, Placebo
Diamyd Medical AB
Type 1 Diabetes Mellitus
12/27
12/27
Spidel, Celee
DIAGNODE-3, NCT05018585 / 2021-002731-32: A Phase III Study to Investigate If the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed with Type 1 Diabetes

Recruiting
3
330
Europe, US, RoW
Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Diamyd, Colecalciferol 2000 IU, Divisun 2000 IU, Placebo
Diamyd Medical AB
Type 1 Diabetes Mellitus
12/27
12/27

Download Options